Professor Chen received her Bachelor’s degree in chemistry (1991) and obtained her PhD degree in Biomedical engineering (1996) from Huazhong University of Science and Technology of China. She worked as a postdoctoral research fellow at the Key Laboratory of Nuclear Analytical Techniques, Institute of High Energy Physics of Chinese Academy of Sciences (1996-1998) and at the Medical Nobel Institute for Biochemistry of Karolinska Institute, Sweden (2001-2002). From 2002 onwards, she has been working as a group and project leader at the China Nanosafety lab. Professor Chen has been awarded the National Award for Innovation and Outstanding Service to the Standard authorised by Standardization Administration of the People’s Republic of China in 2011, the Second Prize of Beijing Science and Technology (ranked second) in 2008, the Second Prize of the National Natural Science Award (ranked second) in 2012.
During her 2 visits to Australia, Professor Chen visited the following labs and gave the following talks:
Professor Chan is currently a Distinguished Professor in the Institute of Biomaterials and Biomedical Engineering at the University of Toronto. Professor Chan received his B.S. degree from the University of Illinois in 1996, PhD degree from Indiana University in 2001, and post-doctoral training at the University of California (San Diego). He moved to Toronto in 2002 to lead the Integrated Nanotechnology/Biomedical Sciences Laboratory. His research interest is in the development and translation of nanotechnology for diagnosing and treating cancer and infectious diseases. He has received NSERC E. W. R. Memorial Steacie Fellowship, Kabiller Young Investigator Award in Nanomedicine, the BF Goodrich Young Inventors Award, Lord Rank Prize Fund award in Optoelectronics (England), and Dennis Gabor Award (Hungary). He is currently an Associate Editor of ACS Nano. Finally, he is also affiliated with a number of different departments at the University of Toronto: Department of Materials Science and Engineering, the Terrence Donnelly Center for Cellular and Biomolecular Research Chemistry, Chemistry and Chemical Engineering.
During his visit to Australia, Professor Chan visited the following labs and gave the following talks:
Professor Wolfgang Parak is the Professor of Experimental Physics at the Philipps-University of Marburg, Germany and head of the Biofunctional Nanomaterials Unit at CIC biomaGUNE, San Sebastian, Spain, He has significantly contributed to the development of new surface chemistries of inorganic nanoparticles and towards the characterization of their physicochemical properties. In particular, the development of an amphiphilic polymer coating is nowadays used by many different groups worldwide.
During his visit to Australia, Professor Parak visited labs and gave talks:
Professor Vince Rotello is the Charles A. Goessmann Professor of Chemistry Professor of Chemistry at UMass Amherst. His research program focuses on using synthetic organic chemistry to engineer the interface between hard and soft materials and spans the areas of devices, polymers, and nanotechnology/bionanotechnology, with over 460 peer-reviewed papers published to date. He is actively involved in the development of new nanomanufacturing methods and in the area of bionanotechnology.
His research includes programs in delivery, imaging, diagnostics and nanotoxicology.
During his visit to Australia Professor Rotello visited labs and gave seminars:
Professor Leaf Huang is a biophysicist at the Eshelman School of Pharmacy at the University of North Carolina. Work in his Laboratory of Drug Targeting focuses on liposomes and immunoliposomes for drug delivery, with current research in siRNA therapy, and receptor mediated drug and vaccine targeting using self-assembled nanoparticles.
During his visit to Australia Professor Huang visited labs and gave seminars:
2014’s Visiting Professor, Mark E. Davis from Caltech, was co-hosted with the Australian Centre for Nanomedicine.
Professor Davis is actively involved in the creation, development and translation of nanoparticle delivery systems for gene silencing and drug delivery in humans. He is the senior author of a Nature paper describing the first example of RNA interference in humans as part of a first-in-human clinical trial of siRNA delivery via targeted nanoparticles for cancer (Nature 2010, 464, 1067).
During his visit to Australia Professor Davis visited labs and gave seminars: